



# Material Safety Data Sheet

ANSI Format

## Tygacil

Preparation Date 09-Jul-2007

Revision Date 08-Dec-2008

Revision Number 5

### 1. PRODUCT AND COMPANY IDENTIFICATION

**Product Name** Tygacil  
**Common Name** Tygacil (Tigecycline) for injection  
**Chemical Name** Not applicable  
**Synonyms** Tigecycline, Tigecycline for Injection, Reformulated Tygacil  
**Product Use** Pharmaceutical product  
**Classification** Anti-infective Agent

**Supplier** Wyeth  
P.O. Box 8299  
Philadelphia, PA 19101 USA.  
Telephone: 1-610-688-4400

**Emergency Telephone Number** Chemtrec USA, Puerto Rico, Canada 1-800-424-9300  
Chemtrec International 1-703-527-3887

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

This is a research material that may affect body functions

**Appearance** Pharmaceutical powder

**Physical State** Solid

**Odor** Not available

#### Potential Physical Hazards

Powders and solids are presumed to be combustible.

#### Potential Health Effects

**Eyes**

May cause mechanical eye irritation

**Skin**

Not available

**Inhalation**

Not available

**Ingestion**

Not available

**Other**

The most common effects may include anaphylaxis photosensitivity pseudotumor cerebri pancreatitis anti-anabolic action superinfection nausea vomiting diarrhea fever abdominal pain blood effects headache hypertension cough increase pain abnormal healing dizziness swelling abscess labored breathing constipation pruritus asthenia/weakness rash hypotension insomnia sweating phlebitis and back pain

May cause harm to the unborn child. May cause harm to breastfed babies.

Please see Patient Package Insert for further information.

**Therapeutic Target Organ(s)**

Systemic

—

Not listed by OSHA, NTP or IARC.

#### Potential Environmental Effects

See Section 12

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Common Name	CAS-No	Composition
Inactive Ingredients	Not applicable	Remainder
Tigecycline	220620-09-7	50 mg/vial
Lactose Monohydrate	64044-51-5	106 mg/vial
Hydrochloric Acid	7647-01-0	As needed to adjust pH
Sodium Hydroxide	1310-73-2	As needed to adjust pH

**4. FIRST AID MEASURES**

<b>Eye Contact</b>	In case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice
<b>Skin Contact</b>	Wash off immediately with soap and plenty of water
<b>Inhalation</b>	Artificial respiration and/or oxygen may be necessary
<b>Ingestion</b>	Immediate medical attention is not required

**5. FIRE-FIGHTING MEASURES**

<b>Flammable Properties</b>	Presumed to be a combustible particulate solid.
<b>Extinguishing Media</b>	
<b>Suitable Extinguishing Media</b>	Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide
<b>Unsuitable Extinguishing Media</b>	Do not use a solid water stream as it may scatter and spread fire
<b>Fire Fighting</b>	Evacuate area and fight fire from a safe distance
<b>Hazardous Combustion Products</b>	Hazardous Combustion Products
<b>Protective Equipment and Precautions for Firefighters</b>	As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear

**6. ACCIDENTAL RELEASE MEASURES**

<b>Personal Precautions</b>	Safety glasses or goggles when splash potential exists
<b>Environmental Precautions</b>	Local authorities should be advised if a significant spill cannot be contained
<b>Methods for Containment</b>	Not available
<b>Methods for Cleaning up</b>	Take up mechanically and collect in suitable container for disposal

**7. HANDLING AND STORAGE**

<b>Handling</b>	Handle in accordance with good industrial hygiene and safety practice
<b>Storage</b>	Keep container tightly closed

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<b>Common Name</b> Tigecycline	<b>Exposure Guideline</b> 70 mcg/m <sup>3</sup>
<b>Engineering Controls</b>	Apply technical measures to comply with the occupational exposure guideline Local exhaust ventilation is needed for open handling or where aerosols may be generated.
<b>Personal Protective Equipment</b>	
<b>Eye/face Protection</b>	Provide eye protection based on risk assessment.
<b>Skin Protection</b>	Wear nitrile or latex gloves. Wear protective garment.
<b>Respiratory Protection</b>	Base respirator selection on a risk assessment.
<b>General Hygiene Considerations</b>	When using, do not eat, drink or smoke
<b>Other</b>	Limit access to only personnel trained in the safe handling of this material Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance

## 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Appearance</b>	Pharmaceutical powder	<b>Physical State</b>	Solid
<b>Color</b>	Orange	<b>Odor</b>	Not available
<b>Odor Threshold</b>	Not available		
<b>pH</b>	4.8		
<b>Specific Gravity</b>	Not applicable	<b>Water Solubility</b>	Not available
<b>Solubility</b>	Not applicable	<b>Evaporation Rate</b>	Not applicable
<b>Partition Coefficient (n-octanol/water)</b>	Not available	<b>Vapor Density</b>	Not applicable
<b>Vapor Pressure</b>	Not applicable		
<b>Boiling Point</b>	Not applicable	<b>Autoignition Temperature</b>	Not applicable
<b>Flash Point</b>	Not applicable	<b>Method</b>	None
<b>Melting Point</b>	Not available		
<b>Flammability Limits in Air</b>	<b>Upper</b> Not applicable	<b>Lower</b> Not applicable	
<b>Explosion Limits</b>	<b>Upper</b> Not applicable	<b>Lower</b> Not applicable	

## 10. STABILITY AND REACTIVITY

<b>Chemical Stability</b>	Stable at room temperature.
<b>Conditions to Avoid</b>	No data available
<b>Materials to Avoid</b>	No materials to be especially mentioned
<b>Hazardous Decomposition Products</b>	None under normal use
<b>Possibility of Hazardous Reactions</b>	None under normal use

## 11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

### Acute Toxicity

#### Tigecycline

LD50 Oral	160 mg/kg rats IV 124 mg/kg male mice 98 mg/kg female mice
-----------	--

Acute Dermal Irritation	Not applicable
-------------------------	----------------

Primary Eye Irritation	Not applicable
------------------------	----------------

Sensitization	Not applicable
---------------	----------------

### Multiple Dose Toxicity

#### Tigecycline

No Toxicologic Effect Dose/Species/Study Length:	Effects on body weight, food consumption, blood, serum chemistry, bone discoloration (rats only), bone marrow, spleen, gastrointestinal tract (dogs only), and kidney were seen in subacute toxicity studies in rats and dogs.
---	--

### Maximum Tolerated Dose (MTD), Oral

#### Tigecycline

Carcinogenicity	No studies to assess the carcinogenic potential have been performed.
-----------------	--

Genetic Toxicity	No evidence of mutagenicity was observed in a battery of <i>in vitro</i> and <i>in vivo</i> assays.
------------------	---

Reproductive Toxicity	See Developmental Toxicity.
-----------------------	-----------------------------

Developmental Toxicity	Animal studies indicate no teratogenicity in rats and rabbits. There was a slight reduction in fetal weights and an increased incidence of musculoskeletal anomalies.
------------------------	---

#### Tigecycline

Target Organ(s) of Toxicity	No data available
-----------------------------	-------------------

## 12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

### Chemical Fate Information

#### Tigecycline

Mobility	Not available
Biodegradability	Inherent biodegradability = 36 % after 46 days.
Stability in Water	Hydrolytically unstable at pH 2-11.
Bioaccumulation	Bioaccumulation is unlikely.

### Ecotoxicity

#### Tigecycline

Microorganisms	EC50/3h/bacteria = 140 mg/l
Algae	Not available
Daphnia	EC50/48h/daphnia = 2.0 mg/l NOEC = 0.39 mg/l
Fish	Not available

## 13. DISPOSAL CONSIDERATIONS

**Waste Disposal Method** Dispose of in accordance with local and national regulations.

## 14. TRANSPORT INFORMATION

**Transport Information** This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)	Not regulated
Canadian Transport of Dangerous Goods (TDG)	Not regulated
International Civil Aviation Organization (ICAO)	Not regulated
International Air Transport Association (IATA)	Not regulated
International Maritime Dangerous Goods (IMDG)/International Maritime Organization (IMO)	Not regulated
Transport of Dangerous Goods by Rail (RID)	Not regulated
Transport of Dangerous Goods by Road (ADR)	Not regulated
Transportation of Dangerous Goods via Inland Waterways (ADN)	Not regulated

## 15. REGULATORY INFORMATION

### USA

#### Federal Regulations

#### **OSHA Regulatory Status**

This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

**SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

**SARA 311/312 Hazardous Categorization**

Acute Health Hazard	No
Chronic Health Hazard	No
Fire Hazard	No
Sudden Release of Pressure Hazard	No
Reactive Hazard	No

This product does not contain any HAPs.

**State Regulations****California Proposition 65**

This product does not contain any Proposition 65 chemicals

**Canada**

Not classified

**WHMIS Hazard Class**

Non-controlled

**European Union**

In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

**Symbol(s)**

Xi - Irritant.  
N - Dangerous for the environment

**R -phrase(s)**

R36 - Irritating to eyes R52 - Harmful to aquatic organisms R63 - Possible risk of harm to the unborn child R64 - May cause harm to breastfed babies

**S -phrase(s)**

S13 - Keep away from food, drink and animal feedingstuffs S25 - Avoid contact with eyes S36 - Wear suitable protective clothing S37 - Wear suitable gloves S38 - In case of insufficient ventilation, wear suitable respiratory equipment S61 - Avoid release to the environment. Refer to special instructions/safety data sheets

---

**16. OTHER INFORMATION****Prepared By**

Wyeth Department of Environment, Health &amp; Safety

**Format**

This MSDS was prepared in accordance with ANSI Z400.1-2004.

**List of References**

See Patient Package Insert for more information.

**Revision Summary**

Change to OEG Changes to Section 2,15

## Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

**End of MSDS**